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Objectives: To develop a generic decision-analytic model
to predict health and economic outcomes of different
management options for cytomegalovirus (CMV) infec-
tion and disease in liver transplant patients.
Methods and Data: The model considers different CMV
management strategies, thereby emphasizing the impor-
tant difference between infection and disease. The ﬁrst
strategy starts with prophylaxis prior to transplantation,
followed by preemptive treatment if infection, based on
positive CMV diagnostic tests, is conﬁrmed. The second
strategy is a preemptive strategy consisting of only testing
followed by preemptive treatment. Finally, in the wait-
and-treat strategy, antiviral treatment is only started
when clinical signs of CMV disease appear. Management
and resource-use data were obtained from clinical experts
in large transplant centers in France, Germany, and the
United Kingdom. Cost data were collected from the
health care payer’s perspective. A Bayesian revision tech-
nique was applied to distinguish effectiveness of current
management options for CMV infection vs. CMV disease,
an aspect that is currently underreported in literature.
Results: CMV prophylaxis in liver transplant recipients is
generally more cost-effective than preemptive and wait-
and-treat strategies. In order of importance, changes in
drug costs, drug efﬁcacy, speciﬁcity of CMV testing, cost
of hospitalization, probability of CMV relapse and base-
line CMV risk are the most important factors inﬂuencing
the cost-effectiveness.
Conclusion: This model describes different strategies
applied for management of CMV in liver transplant
patients and is useful both for current decision making,
optimal disease management, and assessment of future
research targets.
Keywords: analytical model, CMV, cost-effectiveness,
early assessment, liver transplant, preemption, 
prophylaxis.
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ABSTRACT
Introduction
Cytomegalovirus (CMV) is one of the most
common opportunistic infections following solid
organ or bone marrow transplantation. In immuno-
competent persons, clinical CMV infection is infre-
quent [1], but after infection the virus persists in a
latent form in bone marrow progenitor cells or
peripheral blood monocytes. From these sites the
virus can reactivate, and can cause development of
disease leading to severe morbidity and mortality in
immunocompromised patients [1,2]. CMV infec-
tion has a signiﬁcant impact on the overall health
and cost outcomes after transplantation [3–5]. It
has been suggested that reduction of overall post-
transplantation costs can be achieved through
better CMV prevention [3].
Subclinical active CMV infection is deﬁned as:
either detection of CMV-antigen positive cells; iso-
lation of CMV and/or seroconversion; a signiﬁcant
rise in IgG antibodies [6,7]; recovery of virus from
the blood [8]. CMV disease is deﬁned as clinical
signs suggestive of CMV disease in the presence of
active CMV infection [6] or in the presence of virus
isolated from the visceral site [7,8]. Disease may
manifest as “CMV syndrome,” involving fever and
malaise, or as invasion of vital organs such as lungs,
liver or kidneys.
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Current management of CMV infection and
disease consists of either prevention with prophy-
lactic antiviral agents or immunotherapy. Testing
may be performed during prophylaxis; or “testing
and preemption,” whereby patients are monitored
for viral infection and treatment is initiated in case
infection is diagnosed prior to symptoms; or “wait
and treat,” whereby no testing is scheduled, and the
patient is treated as soon as clinical symptoms of
CMV disease appear.
The choice of management strategy is based
mainly on the results of available tests (cultures,
antigenemia assays, polymerase chain reaction) and
on the estimated CMV risk of the patient, depend-
ing on the type of transplant, the immunosuppres-
sive therapy, and the serological status of patient
and donor. Solid transplant patients who are CMV
seronegative (R-) and receive an organ from a
seropositive donor (D +) are at highest risk of CMV
infection [5,9]. Although many transplant centers
apply CMV management algorithms, little attention
has been given to the cost-effectiveness of different
strategies in the literature.
The aim of the current study was to create a
generic decision-analytic model, assessing the health
outcome and the costs of the different therapeutic
approaches to control CMV in transplant recipi-
ents, as well as to assess the cost-effectiveness of
potential new treatment approaches. The generic
model is suitable for analysis in different transplant
patients. This paper describes the model in terms of
its application to liver transplantation.
Methods 
Health-Economic Model
A decision-analytic model was developed using
DATATM from TreeAge (v3.5.7, 2000). The model
is similar in structure to the one described for renal
transplant by Mauskopf et al. [10], and was applied
in the French, German, and UK health-care setting.
The model simulates the natural history up to
one year after transplantation, taking into account
the main clinical outcomes including patient and
graft survival and CMV-related outcomes, i.e.,
CMV infection, CMV disease and CMV-related
mortality. The time horizon of one year allows for
early and late CMV infections reported in the liter-
ature to be taken into account [7]. All CMV-related
outcomes and costs up to one year are taken into
account.
Figure 1 represents the current management
algorithms for CMV: prophylaxis, preemptive
therapy or wait-and-treat. Each strategy is associ-
ated with a risk of CMV infection and CMV
disease.
The prophylactic and preemptive strategies
include diagnostic CMV testing. If CMV tests
become positive without signs of CMV disease, pre-
emptive treatment is initiated. The outcome of pre-
emptive treatment, started only in case of positive
tests for CMV infection, is inﬂuenced by the sensi-
tivity and speciﬁcity of the applied diagnostic tests
as previously reported [2,11,12]. False positive and
true negative tests are not considered to be associ-
ated with the development of CMV disease in the
model, whereas with a false negative or a true 
positive test, CMV disease may develop. In the case
of false negative tests, CMV infection is left
untreated and CMV disease may develop. As for
true positive tests, CMV disease may develop
despite preemptive treatment. If CMV disease
develops treatment intensity depends on the site(s)
of disease manifestation: gastro-intestinal or hepatic
CMV involvement or CMV syndrome, which also
inﬂuence mortality risk.
Prophylaxis, preemption, and wait-and-treat are
the current medical practice regimens considered,
each with its probability based on a survey of expert
opinions of CMV management in each country.
Regimens may differ in choice of drug, intensity of
testing, duration of prevention, and other parame-
ters. The details of the regimens used in a given
strategy are summarized according to country, 
and include all relevant, associated, local medical-
resource uses and costs. The resource use includes
anti-CMV drug treatment, CMV diagnostic testing,
and hospital stays for CMV management. Also, 
for each treatment episode, the cost of associated
adverse events is included. The data tables are
linked directly with the DATATM 3.5 decision tree,
and hence feed cost data to the corresponding
branches of the tree. As such, the model can evalu-
ate the weighted average medical practice in a given
country. Each individual practice regimen can be
analyzed separately by assuming that its probability
is 100%.
Although a causal relationship between CMV
infection and acute transplant rejection has not
been proven, it has been suggested in solid organ
transplant publications, and therefore the model
was programmed to allow this issue to be addressed
in the analysis (Fig. 1), though it was not addressed
in the base-case analysis.
The model includes three CMV-interventions
applied to liver transplant recipients, and for each
strategy, two or three management regimens. The
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baseline risk of CMV (the risk in a wait-and-treat
strategy) is an independent variable that can be
changed to assess the outcome as a function of
patient risk.
The model was designed to evaluate two differ-
ent effectiveness parameters: avoided CMV disease
and avoided mortality. Cost-effectiveness can then
be expressed as cost per CMV disease avoided
(cost/CMV free) and as cost per survivor, or as cost
per life year saved if life expectancy data are avail-
able. The number of avoided CMV disease cases is
a disease speciﬁc effectiveness parameter that is
useful for clinicians. Since the direct economic 
beneﬁts of a reduced number of disease cases are
captured in the numerator, we considered only the
health beneﬁts of avoiding CMV disease in the
denominator. This is comparable for instance to
analyses in the area of coronary heart disease,
where the cost-effectiveness of therapy is expressed
as cost per event free survivor or cost per revascu-
larization avoided [13,14].
Data Applied in the Model
A mail questionnaire was designed to determine
which of the intervention strategies for prophylaxis,
preemption and treatment of CMV disease was
most frequently applied and to identify and measure
the resource use associated with the phases of each
of the strategies. Five experts from universities 
or teaching hospitals in different regions in each
country were selected.
Experts were asked which strategies were applied
currently, and about drug regimens, testing sched-
ules during prophylaxis, preemption or treatment,
and other resource use including hospital stays,
clinic days, specialist visits, follow-up procedures,
management of clinically relevant adverse events,
for each strategy. The measured resource use is
restricted to the incremental resource use as a con-
sequence of CMV management. For example, intra-
venous prophylactic therapy is rarely associated
with an incremental hospital stay because treatment
is initiated and completed during the hospitalization
for the transplant.
Drug regimens included antiviral treatment and
changes in immunosuppressive drugs made in the
event of infection or disease.
Current practice regimens from expert panels in
France, Germany, and the United Kingdom are pre-
sented in summary Tables 1 and 2. The ﬁrst-line
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Figure 1 Analytic model simulating the natural history of CMV prophylaxis, preemption and treatment among liver transplant recipients.
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drug regimens used in prophylaxis, preemption, and
treatment of CMV disease and the testing schedules
performed in prophylaxis and preemption are 
presented.
Second-line antivirals, used when tests fail to
become negative or if symptoms fail to resolve or
when the patient’s condition deteriorates, dose
reductions of immunosuppressive drugs when CMV
infection or disease is diagnosed, testing in case of
CMV disease (e.g., regular cultures, imaging, mon-
itoring of liver and renal function), lengthier hos-
pital stays due to CMV infection or disease, 
and resource use associated with management of
adverse drug reactions are taken into account in
cost calculations as well. Resources were obtained
from the expert panel, and are available upon
request to the authors.
To determine the overall costs of each strategy,
the cost of each item of resource use (drug treat-
ment, days in hospital, tests) is the product of
number of units and the cost per unit. Unit costs
were collected from the health-care payer’s per-
spective, and only direct medical costs were taken
into account.
National formulary lists were the source for drug
unit costs. Country-speciﬁc sources for unit costs
for laboratory tests and imaging procedures were:
Germany, Physician Fee Ordinance; France, NGAP;
United Kingdom, Public Health Laboratory Service
and Royal London NHS trust. Local sources for
Table 1 Basic ﬁrst-line regimens applied in prophylaxis, preemption, and treatment of CMV disease in liver transplant patients.
The last column shows the total cost of each strategy, including drug treatment, testing, management of adverse events, imaging,
and possible increase in hospital stay
Country Subgroup Route (GCV) DD (mg/day) Duration (days) Cost (Euro)
Prophylactic regimens France All PO 1,200 90 2,457
France All IV 350 7
PO 3,000 83 5,688
Germany D+ R– PO 2,400 55 3,206
UK D+ R– PO 3,000 78 4,828
Preemptive regimens* France All IV 700 15 4,616
50% of cases PO 3,000 30
France All PO 2,100 90 9719
20% of cases IV 700 14
Germany PO 2,400 28 1,719
Germany D+ R– IV 700 18 8,356
non D+ R– IV 700 10
UK IV 700 12 8,914
CMV treatment regimens France All IV 770 14
30% IV 350 7 5,525– 6,201*
Germany 100% IV 563 14 8,621–10,568*
UK 100% IV 665 14 8,490– 9,180*
*Ganciclovir.
Abbreviations: D+, seropositive donor; DD, daily dose (mg/day); GCV, ganciclovir; IV, intravenous; PO, per os (oral); R-, seronegative recipient.
Table 2 Testing schedules during prophylaxis and preemption 
Country Tests Duration (months) Total N
Testing during prophylaxis France Viremia 3 4
CMV antibody, qualitative PCR serum 3 6
France Shell vial cultures 1 4
Germany CMV antibody 10 16
Germany Shell vial culture, pp65 antigenemia 3 12
Germany CMV antibody, pp65 antigenemia 1 3
Preemptive testing France CMV antibody 3 4
pp-65 antigenemia 3 16
France CMV antibody, viremia, PCR serum 1 4
Rapid centrifugation culture 1 1
Germany pp-65 antigenemia, qualitative PCR serum 1 4
Germany CMV antibody, pp-65 antigenemia 1 3
Germany Shell vial culture, pp65 antigenemia 3 12
UK Viremia 1 8
PCR serum 0.5 4
Abbreviations: PCR, polymerase chain reaction;Total N, total number of tests performed.
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hospitalization costs were: Germany, German Asso-
ciation of Hospitals; France, Edition Abrégée de la
Comptabilité Analytic Hospitalière des Hopitaux;
and United Kingdom, NHS hospital data.
The different regimens applied in each strategy
(e.g., oral or IV ganciclovir [GVC] for CMV pro-
phylaxis), the risk of CMV infection, CMV disease
and mortality estimates from medical literature
were applied to both average and high-risk patients.
The following search terms, separately or in 
combination were used to search Medline and the
internet: cytomegalovirus, CMV, infection, disease,
epidemiology, liver transplantation, solid organ
transplantation, management, prophylaxis, pre-
emption, clinical trials, mortality. Clinical trial
reports and review articles related to
cytomegalovirus in liver transplantation were
selected. Forty-two publications were reviewed.
Published results of clinical studies were used to
estimate the efﬁcacy of the therapies considered.
These were selected according to the following cri-
teria: prospective controlled clinical trials; relevant
(i.e., reported to be currently applied in the expert
survey) treatment options and regimens; transpar-
ent results of intent-to-treat analysis, sufﬁcient time
horizon (preferably 365 days to include the pos-
sibility of late CMV infections in the model) and
transparent descriptions of patient management. 
Of all articles screened, two fulﬁlled these criteria
[7,15]. Other publications that speciﬁcally ad-
dressed the sensitivity and speciﬁcity of diagnostic
tests for detecting CMV infections were also con-
sidered [2,11,12]. A comprehensive overview of the
clinical trials used to calculate the clinical outcomes
is shown in Table 3.
It is important to note that the overall disease
rate in many prophylaxis trials is often a function
of sequential prophylaxis and preemptive treatment
strategies, which makes it difﬁcult to assess which
of these is responsible for the reduced disease rate.
For instance, Gane et al. [15], report an infection
rate of 51.5% without prophylaxis and a ﬁnal
disease rate of 20.3% with preemptive treatment.
Obviously, the disease rate without preemption
must be estimated to assess the true merits of pre-
emptive treatment in this setting.
Table 4 shows the results of applying a Bayesian
theorem that accounts for the sensitivity and speci-
ﬁcity of pp-65 antigen testing being 0.93 and 0.72,
respectively, and assumes all patients with infection
receive preemptive treatment [2,11,12]. The results
show that in these circumstances, an infection rate
of 55.5% corresponds to a disease rate of 36% if
no patients were treated preemptively. Note that the Ta
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test characteristics applied are based on one study
only.
Applying the calculation described above and the
relative risk reduction for the different strategies
gives an overview of clinical data populating the
model as seen in Table 5.
Based on clinical literature and expert interviews,
it appears that there exists a need for re-preemption
as well as retreatment (for intolerance or for per-
sistence of disease signs after initial preemption or
treatment) in a proportion of patients. Based on 
literature data, base-case values of 20% for re-
preemption and 26% for retreatment were assumed
[16,17].
Only clinically or economically signiﬁcant
adverse events were considered in our analysis. The
identiﬁcation of relevant adverse events was based
on the expert survey according to the following 
criterion: an adverse event leading to a change 
in patient management or in resource consumption
(e.g., decreased dose of concomitant medication,
changed dose or interruption of CMV medication,
additional testing or drugs). Based on the products
applied for CMV management, these relevant
adverse events include grade III-IV severe neu-
tropenia, deﬁned as neutrophil count <109/l, grade
III–IV thrombocytopenia, deﬁned as platelet count
<20 ¥ 109/l, and renal impairment deﬁned as crea-
tininemia >1.5mg/dL. The incidence of adverse
drug reactions was quantiﬁed by selecting those
clinical studies that clearly deﬁned threshold values
for these adverse reactions. When different trials
reporting adverse event rates for the same regimen
were available, and the same adverse event deﬁni-
tions were applied, a pooled result of placebo-
corrected adverse event rates was calculated using
the weighted average method based on sample size.
The incidence and costs of adverse reactions applied
in the model are shown in Table 6.
The cost of managing adverse events was based
on the associated resource use reported by experts.
The parameters considered included drug therapy,
hospitalization, interventions, diagnostic proce-
dures, physician consults as well as dosage reduc-
tions leading to cost reductions. The resource use
and the average costs associated with the different
adverse events were generally comparable among
different countries, although UK cost estimates
were lower than German and French cost estimates.
The costs are generally low because only the incre-
mental cost of the adverse events has been taken
into account. Each treatment episode in the model
is attributed the cost and incidence rate of its respec-
tive adverse events.
The total costs of prophylaxis, preemption, and
treatment of CMV disease per strategy and regimen
are included in Table 1.
The model allows for a variety of sensitivity
analyses to be performed. Two goals of sensitivity
Table 4 Bayesian theorem expressing the relationship
between infection and disease rates
Test Disease Disease
result + - Total
+ 33.6 17.9 51.5 Æ Sensitivity = 0.93
- 2.4 46.1 48.5 Æ Speciﬁcity = 0.72
Total 36.0 64.0 100.0
Table 5 Review of the clinical data reported in literature
for CMV prophylaxis in liver transplant recipients
Outcome Result
Test/preemption CMV infection* 0.515
CMV disease if no preemption 0.349
GCV† fail to preempt 0.525
Disease after preemption 0.203
Treat if disease CMV syndrome 0.487
manifested CMV tissue invasive disease 0.517
Prophylaxis: GCV PO CMV infection 0.245
CMV disease after preemption 0.047
GCV IV CMV infection 0.110
CMV disease after preemption 0.024
*Refers to both true positive and false positive cases.
†GCV: ganciclovir.
Table 6 Overview of key clinical data in the liver model
Neutropenia Thrombocytopenia Renal impairment Source
GCV IV prophylaxis 0.212 0.107 0.06 Pooled*
GCV IV preemption 0.268 0.126 0.06 Boekh, 96
GCV PO prophylaxis 0.03 0.05 0.06 Gane, 97
GCV PO preemption 0.03 0.05 0.06 Gane, 97
Average cost (Euro): France 2333 1884 1565
Germany 1767 888 1123
UK 1713 367 507
*Pooled data: Boekh, 96, and Winston, 95.
Abbreviations: GCV, ganciclovir; IV, intravenous; PO, per os (oral).
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analysis are envisaged: to test the robustness of 
the outcomes, and to perform scenario analyses to
assess the impact of selected interventions on out-
comes. The following variables were considered for
sensitivity analysis: cost of drugs, cost of hospital
stay, cost of adverse events, cost of testing, cost of
consults, cost of nursing, efﬁcacy of prophylaxis,
efﬁcacy of preemption, speciﬁcity of testing, relapse
rates after treatment, and baseline incidence of
disease. One-, two- and three-way sensitivity analy-
ses are possible.
Results
By applying the clinical, resource-use and cost data
to the decision-analytical models, the average
expected costs and effects for each strategy can then
be calculated.
Figure 2 shows the cost-effectiveness results for
the three countries studied, with effectiveness
expressed as avoided CMV disease in average-risk
patients. The advantage of putting the different
countries on the same chart is that in this way,
potential country-speciﬁc differences or similarities
can be identiﬁed.
In the average liver transplant recipient, oral
GVC increases effectiveness at a lower cost. At ﬁrst
glance, the different strategies in the different coun-
tries seem to show a rather consistent cost picture.
Yet, there are some important cost differences
between the different regimens applied within each
strategy. For instance, test and preemptive treat-
ment in the United Kingdom is far more expensive
than in the other two countries. In France, the cost
of intravenous GCV is much higher, for a rather
modest health gain, compared to oral GCV.
Prophylaxis strategies may be either dominant
compared to preemption or have a modest incre-
mental cost-effectiveness ratio (varying from 2700
to 5900 € per case avoided).
Sensitivity Analyses
To assess the impact of uncertainty on the conclu-
sions of the model, sensitivity analyses were per-
formed to show how variation of one or more of
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Figure 2 Cost-effectiveness analysis of the different strategies reported.All costs are in Euros.
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the parameters inﬂuenced the results. These analy-
ses indicated that variation of the baseline incidence
of CMV disease (i.e., the patient’s risk level) had an
important impact on outcomes. Figure 3 shows the
impact of the risk proﬁle of a patient in Germany.
Patients at high risk for CMV disease have a better
outcome with prophylaxis than with the other
strategies. Among low-risk patients, the reverse is
true. Such graphs allow decision makers to deter-
mine thresholds at which to apply prophylaxis.
An overview of the one-way sensitivity analysis
of all key variables is shown in Figure 4 for the
United Kingdom. Each parameter was varied from
80% to 120% of the baseline value, and the effect
of these changes on the cost per case avoided with
GCV prophylaxis was assessed. Note that these
numbers, as in Figure 3, are average cost-
effectiveness ratios. Since all CMV-related costs
have been included in the basecase analysis, this
sensitivity analysis allows us to obtain a rapid and
comprehensive view of the variables that drive the
results. The graph shows that variation of the cost
of drugs by 20% has the strongest impact on the
cost per case avoided. The efﬁcacy of prophylaxis
and the speciﬁcity of testing can also be considered
important elements of the model. As explained
before, such analyses have a dual goal. First, they
can demonstrate the variation of outcomes and the
rank order stability of the results [18]. Indeed, in
the case of increasing cost per case avoided with
prophylaxis, this technique shows whether, at a
given point, preemption would be a better alterna-
tive. If such a point is reached rapidly, the model
outcome is not considered to be robust. In Figure 4
none of the investigated variables lead to a change
in rank order over the 20% variation considered,
implying that the conclusion with respect to cost-
effective prophylaxis is robust.
Results may also be interpreted using strategic
scenario analysis in a disease management context.
Indeed, this technique allows us to assess the impact
of a potential new drug with better efﬁcacy, a drug
that reduces the length of hospital stay, a new test
with better speciﬁcity, or a hospital management
protocol that reduces hospital stay. As such, the
model can be used as a tool for the establishment
of disease management programs. Thereby, two- or
three-way sensitivity analysis allows for the com-
bined assessment of the effect of two or three 
variables (e.g., varying the risk proﬁle of a patient
together with the test speciﬁcity, not shown in
ﬁgures) on outcomes and provides more valuable
disease management information. As an example,
Figure 5 shows a two way sensitivity analysis on the
baseline incidence of CMV disease and the speci-
ﬁcity of testing.
incidence of CMV disease baseline
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Figure 3 Sensitivity analysis of the variable incidence of CMV disease without intervention. Germany, liver transplants. Costs are in Euros.
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Discussion
The model described in this paper can be applied to
two types of objectives. Physicians and clinical
pharmacists may use the framework to compare 
different disease management options in transplant
patients, as a function of risk and available tests.
Developers of new drugs may apply the model to
assess the health-economic consequences of speciﬁc
new features, such as reduced adverse events or
more convenient administration.
The cost drivers in the management of transplant
patients and their inﬂuence on cost-effectiveness
become apparent from the example of liver trans-
plants. Drug costs are the primary cost driver, fol-
lowed by the efﬁcacy of prophylaxis, the speciﬁcity
of testing, and the cost of hospital stay.
In the development of new drugs for CMV man-
agement, an improved safety proﬁle and the avail-
ability of an oral formulation are encouraged from
an economic perspective and in terms of patient
comfort [19,20]. From a health-economic perspec-
tive, these results indicate that reducing hospital
management related to drug administration is a
more signiﬁcant target than is an improved adverse
event proﬁle, when cost per case avoided is used as
a decision parameter. When quality of life is also
taken into account, the results may differ.
The overall costs of prophylaxis, preemption and
CMV disease treatment varied considerably among
centers and countries, and these differences were
largely the result of different hospitalization rates
and hospitalization costs. Previous reports have
conﬁrmed that increased hospitalization after renal
Figure 4 Sensitivity analysis of different variables in the model. Each variable was multiplied by a factor varying from 0.8 to 1.2 (base-case
value = 1). Cost-effectiveness is expressed as Euros per CMV case avoided.
Factorcostdrug 0.8–1.20: Cost of drugs is 20% lower or higher than base case. A higher cost is associated with a higher cost-effectiveness
ratio for prophylaxis.
Factorefﬁcacyproph 0.8–1.20: Efﬁcacy of prophylaxis is 20% (relatively) lower or higher than base case. A higher efﬁcacy is associated with a
lower (= better) cost-effectiveness ratio for prophylaxis.
Factorspeciﬁcity 0.8–1.20: Speciﬁcity is 20% (relatively) lower or higher than base case. A higher speciﬁcity is associated with a lower cost-
effectiveness ratio for prophylaxis.
Factorcosthosp 0.8–1.20: Cost of hospital stay is 20% lower or higher than base case. A higher cost is associated with a lower cost-
effectiveness ratio for prophylaxis.
Factorrelapse 0.8–1.20: Relapse rates after treatment (i.e., need retreatment) is 20% (relatively) lower or higher than base case. A higher relapse
rate is associated with a lower cost-effectiveness ratio for prophylaxis.
Factorincidence 0.8–1.20: Incidence is 20% (relatively) lower or higher than base case. A higher incidence is associated with a lower cost-
effectiveness ratio for prophylaxis.
Factorcostadev: cost of adverse events.
Factorcosttest: cost of testing.
Factorcostcons: cost of consults.
Factorcostnurse: cost of nursing.
Factorefﬁcacypreempt: disease reduction through preemption.
Arrows indicate the direction of the change. Right-pointing arrow: increased drug costs will increase total cost per avoided case. Left-pointing
arrow: increased efﬁcacy of prophylaxis will decrease cost per avoided case.
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transplantation is the most important factor con-
tributing to increased incremental costs due to
CMV infection or disease [4,5,21]. For example,
post-transplant CMV infection was associated with
an average incremental hospital stay of 20 days [3].
These observations underscore the impact of hospi-
tal stay on costs, and illustrate the possibility of
savings as a result of earlier discharge, by switching
from an intravenous to an oral drug formulation
once the patient is stable, for example. It must be
noted, however, that some centers, albeit rarely, are
performing intravenous administrations at home,
enabling earlier discharge despite intravenous drug
therapy.
The use of an expert panel for measurement of
resource use may be criticized as it is based on per-
sonal experience rather than on clinical evidence.
However, it provides a real-life perspective on
resource use rather than one based on the clinical
trial settings. An alternative method could be to
perform a patient chart review. This method would,
however, require a careful screening of the resources
used solely in the context of CMV prevention,
CMV infection or treatment, or alternatively, a
matched-control study design [4]. The preferred
option would be a prospective naturalistic trial
aimed at measuring resource use related to CMV
management. The feasibility of such an approach is
limited by cost and time considerations. Therefore,
the use of an expert panel for measurement of
resource utilization can be justiﬁed in terms of the
aim of the current project [22]. In certain settings,
expert opinion has proven to yield results that are
very similar to those derived from patients chart
analysis [23], although this is not conﬁrmed in
general. Therefore, centers may choose to apply
local audit data when applying the model as a base
for estimating costs and effects of different strate-
gies. Alternatively, ﬁxed treatment algorithms can
also be assessed in this manner.
The best available clinical evidence was selected
on the basis of selection criteria related to the
quality of the published data. The performance of
tests for the diagnosis of CMV infection was also
based on published reports and accounted for in our
analysis. However, it must be noted that for some
of the newer tests such as PCR, there is still evidence
of signiﬁcant variability depending on the test mate-
rials used and the centers experience with the test.
In the future, however, this variability is expected
to decrease as test kits become available.
Prophylaxis performs better in high-risk than 
in average-risk patients. This difference is similar to
previous evaluations of different risk categories
Figure 5. Two-way sensitivity analysis on baseline incidence of CMV disease and speciﬁcity of testing.All combinations in the blue area favor
prophylaxis (higher disease risk, lower cost and less speciﬁc tests in the test /preempt strategy). In low-risk patients and if a high speciﬁcity of
testing was obtained, test/preempt becomes more interesting.
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from an economic point of view, and conﬁrms the
importance of patient selection for treatment allo-
cation [10,20]. In prophylaxis, however, the eco-
nomic advantage of an oral form is limited, since
patients are hospitalized after transplantation for a
long time anyway [21]. This is not the case for the
preemptive treatment, where an oral drug can actu-
ally avoid hospitalization.
Paths to be explored for improving the cost-
effectiveness of CMV management are the opti-
mization of diagnostic test performance, the 
development of new therapeutic entities with better
safety or efﬁcacy than the current therapies, and
therapies that can be administered at home (e.g., an
oral formulation with equal bio-availability as the
intravenous form).
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